Endocrine Abstracts

Objective: Sclerostin, a circulating Wnt antagonist and a main negative regulator of bone formation, is increased in type 2 diabetes (T2DM). No data are available on latent autoimmune diabetes in adults (LADA) and whether sclerostin is affected by metabolic syndrome (MS) associated with T2DM or LADA. We evaluated serum sclerostin and bone turnover markers in LADA and T2DM in relation with MS.Research design and methods: This cross-sectional study include...